And this is why I was so filthy with Scott Richards when the Nuvaring generic application had to be re-submitted to the FDA. Since 2018 we've been told how Nuvaring generic was going to be so good for the company with the launch expected in the 2019FY. It was used as the carrot (or Black Swan if you like) while we kept on getting bashed with the Net Losses and impairment stick in the last 3 years. Now Nuvaring generic barely rates a mention and all of the focus is on Nextstellis. It stinks of management just crossing their fingers and hoping that a rabbit / black swan comes out of a hat to save them.
MYX Price at posting:
30.5¢ Sentiment: Sell Disclosure: Held
